NasdaqGS - Delayed Quote USD

Ascendis Pharma A/S (ASND)

173.06
-4.49
(-2.53%)
At close: June 6 at 4:00:01 PM EDT
173.06
0.00
(0.00%)
After hours: June 6 at 4:58:43 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Jan Moller Mikkelsen President, CEO, Member of Executive Board & Executive Director -- -- 1960
Mr. Scott T. Smith CFO, Executive VP & Member of Executive Board -- -- 1974
Ms. Pedersen Anni Lotte Kirstine Sonderbjerg Executive VP, Chief Administrative Officer & Member of the Executive Board -- -- 1961
Mr. Michael Wolff Jensen L.L.M. Executive VP, Chief Legal Officer & Member of the Executive Board -- -- 1971
Mr. Mads Bodenhoff Senior VP, Head of Finance & Principal Accounting Officer -- -- 1969
Mr. Flemming Steen Jensen Executive Vice President of Product Supply & Quality -- -- 1961
Dr. Kennett Sprogoe Ph.D. Executive VP and Head of Research & Product Development -- -- 1979
Dr. Stina Singel M.D., Ph.D. Executive VP & Head of Clinical Development for Oncology -- -- 1974
Mr. Joseph Kelly Head of U.S. Commercial of Endocrinology -- -- 1969
Ms. Sherrie Glass Chief Business Officer -- -- --

Ascendis Pharma A/S

Tuborg Boulevard 12
Hellerup, 2900
Denmark
45 70 22 22 44 https://ascendispharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
1,017

Description

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Corporate Governance

Ascendis Pharma A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

September 1, 2025 at 10:59 AM UTC - September 5, 2025 at 12:00 PM UTC

Ascendis Pharma A/S Earnings Date

Recent Events

June 2, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 28, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 1, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

April 29, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

April 9, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

March 31, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

March 28, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

March 20, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

March 12, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

February 27, 2025 at 12:00 AM UTC

S-8: Offering Registrations

Related Tickers